Monashee Investment Management’s Solid Biosciences SLDB Stock Holding History

Monashee Investment Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5M	Sell	500,000 -920,295	-65%	-$6.98M	8.38%	3
2026 Q1	$10.2M	Buy	1,420,295 +70,524	+5%	+$453K	5.56%	6
2025 Q4	$7.61M	Buy	+1,349,771	New	+$7.32M	4.29%	10
2025 Q3	–	Sell	-2,165,000	Closed	-$10.5M	–	82
2025 Q2	$10.5M	Buy	2,165,000 +491,588	+29%	+$1.74M	3.82%	7
2025 Q1	$6.19M	Buy	1,673,412 +1,193,412	+249%	+$5.11M	0.73%	19
2024 Q4	$1.92M	Sell	480,000 -5,000	-1%	-$27.5K	0.26%	31
2024 Q3	$3.38M	Buy	485,000 +35,000	+8%	+$284K	0.37%	40
2024 Q2	$2.55M	Sell	450,000 -170,000	-27%	-$1.52M	0.33%	36
2024 Q1	$8.26M	Buy	+620,000	New	+$5.8M	0.98%	16

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Monashee Investment Management's SLDB Position: Q2 2026 in Review

Monashee Investment Management reduced its Solid Biosciences (SLDB) stake by 65% in Q2 2026, selling an estimated $6.98M and leaving 500,000 shares worth $5M. The position accounts for 8.38% of the portfolio, ranked #3.

Monashee Investment Management first reported a position in SLDB in Q1 2024 and has held it in 9 quarters since. The position peaked at $10.5M in Q2 2025. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Monashee Investment Management held 500,000 shares of Solid Biosciences worth $5M as of Q2 2026.
Monashee Investment Management sold 920,295 Solid Biosciences shares in Q2 2026, an estimated $6.98M.
Solid Biosciences made up 8.38% of Monashee Investment Management's portfolio in Q2 2026, its #3 holding.
Monashee Investment Management first reported a position in Solid Biosciences in Q1 2024 and has held it in 9 quarters since.
Monashee Investment Management's Solid Biosciences position peaked at $10.5M in Q2 2025.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.